Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland

Suvi-Päivikki Sinikumpu1, Juha Auvinen2,3, Jari Jokelainen2,3, Laura Huilaja1, Katri Puukka4, Aimo Ruokonen4, Sirkka Keinänen-Kiukaanniemi2,3, Kaisa Tasanen1 & Markku Timonen3

Diabetes is an undiagnosed disease and easy screening tools for it are warranted. Because foot complications are usual in diabetes, we aimed to test hypothesis that skin abnormalities are found already from patients who are not aware of having diabetes, by studying the possible association between unhealthy toe web skin and abnormal glucose metabolism. 1,849 cases without previously diagnosed diabetes participated to the 46-year follow-up study of the Northern Finland Birth Cohort. A skin investigation was performed for all, and abnormal skin findings in toe web spaces were taken as explanatory variables. Abnormal glucose tolerance was the main outcome and it was tested with an oral glucose tolerance test (OGTT), glycosylated haemoglobin fraction (HbA1c). Values are numbers (percentages) of sub and fasting blood glucose. The participants who had any abnormal skin findings in toe webs were associated with 2.5-fold (OR 2.5, 95% CI 1.3–4.9) and 6-fold (OR 6.2, 1.4–27.6) increased risk of having previously undiagnosed diabetes detected by a 2-hour OGTT and HbA1c, respectively. The predictive power of toe web findings was comparable with FINDRISC score. Abnormal skin findings in the toe webs show increased risk of occult diabetes, and may, thus serve as an additional sign of undiagnosed diabetes.

Disrupted micro- and macrovascular architecture caused by abnormal glucose metabolism may result in increased complications in the feet of diabetes patients1. Foot complications are one of the most common reasons for hospitalization of patients with diabetes2,3. Among these complications, diabetic ulcers are the most common4, presenting in 2–5% of patients every year and this complication is seen in 15–25% of patients with diabetes at some point during their disease duration5,7. Diabetic ulcer precedes lower limb amputation in 80% of cases6 and gangrene, cellulitis and other skin infections can be life threatening6,8,9.

A lot of work has been done to prevent diabetic foot complications, e.g. by means of the National Institute for Health and Clinical Excellence (NICE) guidelines for diabetic foot problems. However, given that half of all adult patients with diabetes are still not diagnosed1, there is an unmet need not only for secondary prevention of complications but also for early detection and primary prevention of diabetes itself. Diabetes Risk Scores such as FINDRISC questionnaire is one of those tools that has been utilized to identify individuals at high risk of diabetes10. Based on the high incidence of foot problems in diabetes patients per se it is reasonable to hypothesize that abnormalities of the foot skin might also be found in individuals who are not yet aware of having diabetes or prediabetes stage. We tested this hypothesis – by first performing comprehensive clinical investigations of foot skin and oral glucose tolerance tests (OGTT), and recording fasting plasma glucose (FPG) and glycosylated

1PEDEGO Research Unit, University of Oulu, Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, P.O. Box 20, Oulu, 90029, Finland. 2Unit of General Practice, Oulu University Hospital, P.O. Box 10, Oulu, 90029, Finland. 3Centre for Life Course Health Research, University of Oulu, P.O. Box 5000, Oulu, 90014, Finland. 4NordLab Oulu, Department of Clinical Chemistry and Medical Research Center Oulu, University Hospital of Oulu, P.O. Box 500, Oulu, 90029, Finland. Correspondence and requests for materials should be addressed to S.-P.S. (email: suvi-paivikki.sinikumpu@oulu.fi)
haemoglobin fraction (HbA1c) in birth cohort participants - to determine any association between skin findings in the toe web spaces and previously undiagnosed diabetes or prediabetes.

Results
Characteristics of study population and toe web findings. A total of 3,181 cohort members were invited to participate in the study; of these, 1,930 (60.7%) agreed and were examined by the dermatologists. All study participants were 45–46 years old at the time of data collection; 53.6% were females. A total of 81 participants (4.2%) had previously diagnosed diabetes (prDM) and they were excluded from the present study, and, consequently the rest study cases formed our final study population (N = 1,849). FPG was recorded in 1,804 (97.6%) of participants (data missing from 45 [2.4%]) and HbA1c data were available from 1,838 (99.4%) (data missing from 11 [0.6%]). Altogether, 1,571 (85.0%) attended OGTT, and 1,554 (84.0%) completed the test. (S1, Table 1). The reasons for missing laboratory data were that all study cases did not attend the OGTT or that some of blood samples or their analysis were not eligible.

Abnormal skin features were found in the toe web spaces of 26.6% (N = 492/1,849) of the participants. They were found significantly more often in males (36.7%, N = 316) compared to females (17.8%, N = 176) (P < 0.001). (Tables 1 and 2).

Glucose metabolism. Among study participants FPG was elevated (6.1–6.9 mmol/L) in 9.5% (N = 172/1,804) and 1.2% (N = 21/1,804) presented diabetic value of ≥7.0 mmol/L. HbA1c was elevated (5.7–6.4%) in 21.6% of the study cases (N = 397/1,838) and it was at diabetic level (≥6.5%) in 0.8% (N = 15/1,838). According to OGTT test, 2.8% (N = 43/1,554) had screen-detected diabetes (SDM), impaired fasting glycaemia (IFG) was found in 7.9% (N = 121/1,554) of the study participants and 8.6% (N = 134/1,554) had impaired glucose tolerance (IGT).

Association of skin findings in toe web spaces and glucose metabolism. Subjects with abnormal skin findings in the toe webs had a 2.5-fold greater risk of having SDM by the OGTT than those without abnormal findings (adjusted odds ratio (OR) 2.48, 95% confidence interval (CI) 1.3–4.9; P = 0.01). The corresponding separate analyses with regard to 0-h (fasting) and 2-h values in 2-h OGTT are presented in Fig. 1. Diabetic HbA1c levels were also more common in participants with abnormal toe web findings (1.8%, N = 9/492), compared to those with healthy skin (0.4%, N = 6/1,357) (adjusted OR 6.2, 95% CI 1.4–27.6; P < 0.001). The association of skin changes in toe web spaces between IFG and IGT did not reach the level of statistical significance after the adjusting for confounding variables (adjusted OR 1.01, 95% CI 0.65–1.55; P = 0.98 and adjusted OR 0.89, 95% CI 0.58–1.37; P = 0.60 for IFG and IGT, respectively) (Table 2) (Fig. 1).

The predictive power of toe web space finding. Multivariate logistic regression analyses demonstrated that both FINDRISC score and toe webs finding were independent risk factors to predict diabetes risk (i.e. SDM) in our study population (adjusted OR for FINDRISC was 1.5, 95% CI 1.3–1.6 and for toe web finding 2.3, 95% CI 1.2–4.2; P < 0.01 for both). When the toe web finding was added to the original FINDRISC model10, the β-coefficient for toe web finding was 0.82, which corresponds to a score of 3 in the FINDRISC test10. The AUC, the area under the receiver operating characteristic (ROC) curve, was 0.834 for the original FINDRISC score and 0.839 for the risk score modified with toe web finding.

Discussion
The central finding of our general population-based study was that, after adjusting for confounding variables, abnormal skin findings in the toe web spaces were associated with an elevated risk of having SDM. The corresponding risk was 2.5-fold, and even over 6-fold higher when elevated 2-h glucose, and HbA1c, respectively, were used as a definition of SDM.

There are several clinical findings, such as high blood pressure and obesity, that are associated with diabetes mellitus and their appearance may, therefore, result in suspicion of the diabetes11, 12. Further, impaired reflexes13, vision14, increased urinating15 and cardiac ischemia16 are other common symptoms that can precede a diagnosis of diabetes. To best of our knowledge, this is the first study to investigate the association between skin changes in the toe web spaces and prediabetes or undiagnosed diabetes using clinical skin examinations and an OGTT as well as blood tests.

Significant effort has been made to develop practical, easy, fast and non-invasive screening tools for to identify persons who are unknowingly at high risk of type 2 diabetes17. Of those, one of the most widely used screening tools among Caucasians is FINDRISC questionnaire which has been described to identify up to 66% of males and 70% of females of previously undiagnosed patients with type 2 diabetes10. In order to test the predictive power of abnormal toe webs finding we compared it to FINDRISC score. These analyses revealed that toe webs finding is an independent risk factor to predict diabetes risk: the β-coefficient for the toe web finding was corresponding to a score of 3 in the FINDRISC test and is therefore comparable to body mass index or waist circumference as a risk factor. However, our variable did not add much to the predictive power of the statistical model, since the AUC for the FINDRISC modified with the toe web finding was only slightly higher than that of the original FINDRISC score. Albeit toe web finding is an independent risk factor in risk score, its clinical importance at population level requires future studies.

There are some theoretical explanations for the overrepresentation of skin changes in abnormal glucose metabolism; both hyperglycaemia and decreased insulin signal affect skin function18. Insulin is an important growth factor of keratinocytes and is involved in their proliferation, migration and differentiation19. When the insulin balance is disrupted, the functions of keratinocytes are impaired, the epidermal barrier is disrupted and wound healing worsens20. In hyperglycaemia the concentration of cutaneous glucose increases and the pH of...
| Variables                                         | Male          | Female         | P value* |
|--------------------------------------------------|---------------|----------------|----------|
| Skin changes in toe web spaces:                  |               |                | <0.001   |
| No                                               | 545 (63.3)    | 812 (82.2)     |          |
| Yes                                              | 316 (36.7)    | 176 (17.8)     |          |
| OGTT status:                                     |               |                | <0.001   |
| Normal glucose tolerance                         | 542 (74.3)    | 714 (86.5)     |          |
| Impaired fasting glycaemia                        | 92 (12.6)     | 29 (3.5)       |          |
| Impaired glucose tolerance                       | 73 (10.0)     | 61 (7.4)       |          |
| Screen-detected diabetes                          | 22 (3.0)      | 21 (2.5)       |          |
| OGTT 0-h glucose (mmol/L)^†:                      | 5.7 (0.6)     | 5.3 (0.6)      | <0.001   |
| OGTT 0-h glucose^‡:                              |               |                | <0.001   |
| Normal                                           | 593 (80.5)    | 773 (92.7)     |          |
| Elevated                                         | 127 (17.2)    | 50 (6.0)       |          |
| Diabetic                                         | 17 (2.3)      | 11 (1.3)       |          |
| OGTT 2-h glucose (mmol/L)^‡:                      | 6.0 (1.6)     | 5.9 (1.6)      | 0.676    |
| Normal                                           | 644 (88.3)    | 750 (90.9)     |          |
| Elevated                                         | 77 (10.6)     | 62 (7.5)       |          |
| Diabetic                                         | 8 (1.1)       | 13 (1.6)       |          |
| Fasting plasma glucose (mmol/L)^‡:                | 5.6 (0.7)     | 5.2 (0.5)      | <0.001   |
| Normal                                           | 698 (83.4)    | 909 (94.0)     |          |
| Elevated                                         | 121 (14.5)    | 51 (5.3)       |          |
| Diabetic                                         | 18 (2.2)      | 7 (0.7)        |          |
| Fasting HbA1c (mmol/mol)^‡:                       | 36.1 (5.2)    | 35.0 (3.8)     | <0.001   |
| Fasting HbA1c (%)^‡:                              | 5.5 (0.5)     | 5.4 (0.4)      | <0.001   |
| Fasting HbA1c (%)‖:                               |               |                | <0.001   |
| Normal                                           | 632 (73.7)    | 794 (80.9)     |          |
| Elevated                                         | 214 (25.0)    | 183 (18.7)     |          |
| Diabetic                                         | 11 (1.3)      | 4 (0.4)        |          |
| Education:                                       |               |                | 0.276    |
| Basic/Secondary                                  | 539 (62.6)    | 593 (60.0)     |          |
| Tertiary                                         | 322 (37.4)    | 395 (40.0)     |          |
| Smoking status^#:                                 |               |                | <0.001   |
| Never smoked                                      | 392 (47.4)    | 553 (58.0)     |          |
| Former smokers (>6kk)                            | 232 (28.1)    | 217 (22.8)     |          |
| Former smokers (<6kk)                            | 18 (2.2)      | 12 (1.3)       |          |
| Current smokers                                  | 185 (22.4)    | 171 (17.9)     |          |
| Physical activity^#:                             |               |                | <0.001   |
| Inactive                                         | 157 (19.0)    | 209 (21.9)     |          |
| Lightly active                                   | 324 (39.3)    | 364 (38.1)     |          |
| Active                                           | 301 (36.5)    | 365 (38.2)     |          |
| Very active                                      | 43 (5.2)      | 17 (1.8)       |          |
| Body mass index (kg/m²)^‡:                        | 27.1 (4.0)    | 26.4 (5.2)     | <0.001   |
| Body mass index (kg/m²):                         |               |                | <0.001   |
| Underweight                                      | 2 (0.2)       | 6 (0.6)        |          |
| Normal                                           | 266 (30.9)    | 468 (47.5)     |          |
| Overweight                                       | 431 (50.1)    | 303 (30.7)     |          |
| Obese                                            | 134 (15.6)    | 142 (14.4)     |          |
| Severely Obese                                   | 28 (3.3)      | 67 (6.8)       |          |

Table 1. The characteristics of the cohort study population concerning skin findings in toe web spaces, glucose metabolism and confounding factors according to sex. Values are numbers (percentages) of subjects unless stated otherwise. *The Mann-Whitney U-test was used when testing continuous variables and Chi-Square test or Fisher exact test for categorical variables. †Values are mean (standard deviation, SD). ‡OGTT: 1,571 study cases first attended and 1,554 of them completed OGTT. OGTT was not conducted if FPG was <8.0 mmol/l just before the test (n = 11). OGTT 0-h or OGTT 2-h was not eligible in six (n = 6) study cases. N = 278 did not attend the OGTT. §Data of FPG was missing from n = 45. †Data of HbA1c was missing from n = 11. ‡Data of smoking status and physical activity was missing from n = 69 (The reason was missing data was that all study cases did not fill health questionnaires). †Data of body mass index was missing from n = 2 (The reason for missing data was that all study cases did not come to the weighing).
### Table 2. Skin findings in toe web spaces and its associative factors. Values are numbers (percentages) of subjects unless stated otherwise. *The Mann-Whitney U-test for used when testing continuous variables and Chi-Square test or Fisher exact test for categorical variables. †Values are mean (standard deviation, SD). ‡OGTT: 1,571 study cases first attended and 1,554 of them completed OGTT. OGTT was not conducted if FPG was <8.0 mmol/l just before the test (n = 11). OGTT 0-h or OGTT 2-h was not eligible in six (n = 6) study cases. N = 278 did not attend the OGTT. §Data of FPG was missing from n = 45. ‖Data of HbA1c was missing from n = 11. #Data of smoking status and physical activity was missing from n = 69 (The reason was missing data was that all study cases did not fill health questionnaires). ¶Data of body mass index was missing from n = 2 (The reason for missing data was that all study cases did not come to the weighing).

| Variables                      | Skin findings in toe web spaces | P value* |
|--------------------------------|--------------------------------|----------|
|                                | No                | Yes             |         |
| Sex:                           |                   |                 | <0.001  |
| Male                           | 545 (40.2)        | 316 (4.2)       |         |
| Female                         | 812 (59.8)        | 176 (35.8)      |         |
| OGTT status:                   |                   |                 | <0.001  |
| Normal glucose tolerance      | 954 (83.1)        | 302 (74.4)      |         |
| Impaired fasting glycemia      | 79 (6.9)          | 42 (10.3)       |         |
| Impaired glucose tolerance     | 96 (8.4)          | 38 (9.4)        |         |
| Screen detected diabetes       | 19 (1.7)          | 24 (5.9)        |         |
| OGTT 0-h glucose (mmol/L):     | 5.5 (0.5)         | 5.7 (0.8)       | <0.001  |
| OGTT 0-h glucose§:            |                   |                 | <0.001  |
| Normal                         | 1033 (89.1)       | 333 (81.0)      |         |
| Elevated                       | 114 (9.8)         | 63 (15.3)       |         |
| Diabetic                       | 13 (1.1)          | 15 (3.6)        |         |
| OGTT 2-h glucose (mmol/L):     | 5.9 (1.5)         | 6.0 (1.8)       | 0.978   |
| OGTT 2-h glucose§:            |                   |                 | 0.003   |
| Normal                         | 1043 (90.6)       | 351 (87.1)      |         |
| Elevated                       | 99 (8.6)          | 40 (9.9)        |         |
| Diabetic                       | 9 (0.8)           | 12 (3.0)        |         |
| Fasting plasma glucose (mmol/L):| 5.4 (0.6)         | 5.6 (0.8)       | <0.001  |
| Fasting plasma glucose (mmol/L):|                 |                 | 0.001   |
| Normal                         | 1196 (90.5)       | 411 (85.3)      |         |
| Elevated                       | 114 (8.6)         | 58 (12.0)       |         |
| Diabetic                       | 12 (0.9)          | 13 (2.7)        |         |
| Fasting HbA1c (mmol/mol)^†:     | 35.2 (4.3)        | 36.4 (5.1)      | <0.001  |
| Fasting HbA1c (%)^†:           | 5.4 (0.4)         | 5.5 (0.5)       | <0.001  |
| Fasting HbA1c (%)^‡:           |                   |                 | <0.001  |
| Normal                         | 1077 (79.8)       | 349 (71.5)      |         |
| Elevated                       | 267 (19.8)        | 130 (26.6)      |         |
| Diabetic                       | 6 (0.4)           | 9 (1.8)         |         |
| Education:                     |                   |                 | 0.005   |
| Basic/Secondary                | 804 (59.2)        | 328 (66.7)      |         |
| Tertiary                       | 553 (40.8)        | 164 (33.3)      |         |
| Smoking status^#:              |                   |                 | 0.002   |
| Never smoked                   | 713 (54.3)        | 232 (49.6)      |         |
| Former smokers (>6kk)          | 339 (25.8)        | 110 (23.5)      |         |
| Former smokers (<6kk)          | 25 (1.9)          | 5 (1.1)         |         |
| Current smokers                | 235 (17.9)        | 121 (25.9)      |         |
| Physical activity#:            |                   |                 | 0.029   |
| Inactive                       | 258 (19.7)        | 108 (22.8)      |         |
| Lightly active                 | 509 (38.9)        | 179 (37.8)      |         |
| Active                         | 504 (38.6)        | 162 (34.2)      |         |
| Very active                    | 36 (2.8)          | 24 (5.1)        |         |
| Body mass index (kg/m²)^†:     | 26.3 (4.5)        | 27.9 (5.1)      | <0.001  |
| Body mass index (kg/m²)^‡:     |                   |                 | <0.001  |
| Underweight                    | 6 (0.4)           | 2 (0.4)         |         |
| Normal                         | 590 (43.5)        | 144 (29.3)      |         |
| Overweight                     | 521 (38.5)        | 213 (43.3)      |         |
| Obese                          | 181 (13.4)        | 95 (19.3)       |         |
| Severely Obese                 | 57 (4.2)          | 38 (7.7)        |         |
intertriginous regions of the skin surface rises, favoring colonization of microbes. Furthermore, diabetes causes decreases in sebaceous gland activity and skin hydration resulting in dry skin that is still more vulnerable to infections. Finally, other complications associated with diabetes, such as vascular sclerosis and neuropathy also increase the risk of skin complications. Fungal skin infections have been reported to be present up to 30–80% of people with diabetes, and might be due to these earlier mentioned theoretical explanations. Tinea pedis, which is the most common fungal skin infection in general and in patients with diabetes, is typically found in the toe web spaces between the fourth and fifth toes and is characterized by maceration, peeling or erythema. Consequently, our findings in toe web spaces might be explained mainly because of tinea pedis. The early detection of diabetes and subsequent foot care is important in order to prevent complications of diabetes. These complications may initially manifest as interdigital toe web maceration that can progress towards fulminant infections like erysipelas, cellulitis, sepsis and osteomyelitis and even to diabetic ulcer.

Toe web skin and glucose metabolism were investigated in a large general population. Skin examination was performed for nearly 2,000 study participants by a specialist in dermatology or by an experienced resident instead of self-reporting. Maceration, vesicles or localized erythema in the toe webs were recognized as abnormalities considering that they are findings that can easily be found in the adult population by subjects themselves or by an expert other than a dermatologist. No specific instruments or laboratory tests such as fungal culture were needed: a visual investigation was sufficient to determine unhealthy toe webs. This emphasizes the importance of our primary finding, because it means that self-determined problems in the toe web spaces may function as the first signal of undiagnosed diabetes thus enhancing the early detection of diabetes. At 60.7%, the participation rate was satisfactorily high. Finally, glucose metabolism was tested with HbA1c and fasting glucose for nearly 2,000 and with OGTT for nearly 1,600 study cases.

One weakness of our study was that we did not take any culture samples of toe web spaces and it was impossible to determine whether such samples would have revealed fungal, yeast or bacterial infection in the skin. Nevertheless, visible risk factors (toe web space abnormalities) are more important from the prevention point of view and therefore, when designing our study, we gave preference to clinical status over culture as our candidate sign of prediabetes or diabetes. Abnormalities in toe web spaces are usually easy to notice. However, the signs can be so slight that they are easily ignored by individuals themselves or even by their doctors, and their clinical importance can be overlooked.

According to the findings of our study, unhealthy toe web spaces could also be taken into account to enhance the detection of diabetes; maceration, scales, vesicles or localized erythema in the toe web spaces may be one sign of abnormal glucose metabolism in middle-aged people who are not aware that they have diabetes. Our population was predominantly made up of subjects in early middle-aged, and since, the onset of diabetes usually occurs later in adulthood, the association between abnormal toe web space findings and decreased glucose tolerance should be evaluated as a future research in older people.
Research Design and Methods

Study design and population. This is a cross-sectional general population study that belongs to the Northern Finland Birth Cohort 1966 (NFBC1966), which is a longitudinal research program. NFBC1966 initially included all 12,058 children in the two northernmost provinces in Finland whose expected days of birth were between 1st of January and 31st of December 1966. The whole cohort has been evaluated regularly since birth by means of health questionnaires and clinical examinations.

When the NFBC1966 study participants reached the age of 46 years, all those living within 100 km of the centre of the city of Oulu (N = 3,181) were invited to participate in a multidisciplinary health study, which included comprehensive clinical health examination and questionnaires. This study included a clinical skin examination and detailed inspection of feet, extraction of fasting blood samples and, on a separate day, a 2-hour OGTT. Data were collected between April 2012 and May 2013.

Clinical skin examination. A comprehensive dermatological examination was performed for 1,930 participants by a dermatologist or an experienced resident. This full skin examination also included a detailed inspection of the toe web spaces and the skin surrounding them to detect any sign of abnormal findings. In particular maceration, scales, vesicles or localized erythema were systematically recorded as abnormal cutaneous findings of the toe web spaces. (Fig. 2).

Glucose metabolism. In connection with clinical health examination, venous blood samples were used to determine fasting plasma glucose and HbA1c—values of every eligible participant. Blood samples were taken at the cohort laboratory between 7:00 and 11:00 a.m. after an over-night fast. Patients whose fasting plasma glucose was <8.0 mmol/L and had no previous diagnosis of diabetes underwent an OGTT with a 75 g glucose load, after which a 2-hour plasma sample was collected. Previously diagnosed diabetes (PrDM) was defined according to self-reported diagnoses and medications, hospital outpatient and inpatient registers and medication registers from the Social Insurance Institution of Finland. A total of 81 participants had prDM and they were excluded from the study. The concentration of HbA1c and the concentration of total haemoglobin were measured by immunochemical assay method. Glucose were analysed using an enzymatic hexokinase/glucose-6-phosphate dehydrogenase method. (both method: Advia 1800; Siemens Healthcare Diagnostics Inc., Tarrytown, Ny, USA). The samples were analysed in NordLab Oulu, a testing laboratory (T113) accredited by Finnish Accreditation Service (FINAS) (EN ISO 15189).

Glucose tolerance status was classified according to World Health Organization (WHO) criteria as follows:

- normal glucose tolerance (NGT) was defined as having a FPG level <6.1 mmol/L and a 2-hour post-load glucose level <7.8 mmol/L
- IGT was defined by a FPG level <7.0 mmol/L and a 2-hour glucose level of 7.8–11.1 mmol/L
- IFG was defined by a FPG level between 6.1- and 6.9 mmol/L and a 2-hour glucose level <7.8 mmol/L
- SDM was defined by either a FPG level ≥7.0 mmol/L or a 2-hour glucose level ≥11.1 mmol/L.

HbA1c was defined as normal when <5.7%, elevated when 5.7–6.4% and diabetic when ≥6.5% according to American Diabetes Association (ADA).

Confounding factors. Body mass index, smoking, leisure time physical activity and socioeconomic status were considered as potentially confounding factors in the analyses because they have all been associated with skin changes and abnormal glucose metabolism.

Body mass index was determined according to the measured weight (kg) and height. Study participants were classified into five groups according to body mass index: Underweight <18.5; normal 18.5–25; overweight 25–30; obese 30–35 and severely obese >35.

Smoking status was reported in postal questionnaires at the age of 46 years using the following questions: 1) Have you ever smoked? 2) Have you ever smoked regularly, almost daily for at least a year? 3) Do you currently smoke? 4) When was the last time you smoked? According to the answers the respondents were divided into four categories.
groups: current smokers (those who smoked regularly and who had smoked in the last month); former smokers <6 months (those who had smoked regularly but had quit smoking less than six months ago), former smokers >6 months (those who had smoked but had quit more than six months ago), and 4) never smoked (those who had never smoked regularly for at least a year).

Leisure time physical activity was self-reported. Reporting concerned the frequency of participation to physical and recreational activities in leisure time and the study cases were classified into four groups: Inactive (those who preferred to stay indoors reading or watching television and did not like sports much); Lightly active (those who exercised at least four hours per week e.g. by walking, cycling, fishing); Active (those who liked fitness training and had e.g. running, swimming or skiing as a regular sport activity for at least two hours per week); Very active (those who exercised several hours per week by running, practicing orienteering or playing ball games).

Socioeconomic status was categorised on education level, because that has been defined as the most specific indicator of socioeconomic status41. Data concerning education were obtained from the National Education Register and were supplemented by self-reported questionnaires regarding personal educational history42.

Statistical analyses. The main outcome measures were OGTT status (NGT, IFG, IGT, SDM or prDM), FPG and HbA1c while skin findings in toe web space (normal vs. abnormal) was an explanatory variable. The skin was defined as abnormal if at least one of the following was found: maceration, scales, vesicles or localized erythema. Distributions of continuous variables were expressed as mean and standard deviation (SD), and categorical variables as proportions. Continuous variables were tested using the Mann-Whitney U-test. The Chi-Square test or Fisher’s exact test were used for categorical variables, as appropriate. The risk factors associated with abnormal glucose metabolism in participants (examined by OGTT, FPG and HbA1c) were analysed using a multivariate multinomial logistic regression technique. Skin findings in toe web spaces were analysed for correlation with abnormal glucose metabolism. Adjustments were made for smoking physical activity, education, sex and body mass index. An established clinical FINDRISC score for type 2 diabetes was chosen as a reference tool against findings in toe web spaces. The logistic regression analysis was used to evaluate the risk for diabetes (i.e. SDM) both with FINDRISC score and with toe web finding. The FINDRISC risk score was modified by adding toe web finding as an additional variable into the FINDRISC model and logistic regression analyses was performed according to the methodology in the original publication by Lindström and Tuomilehto10 in order to test if toe web finding gives predictive power to this establish clinical risk score. The area under the receiver operating characteristic (ROC) curve, known as the AUC, was defined for FINDRISC and for risk score modified with toe web finding. ORs (crude and adjusted) with related 95% CI were reported as measures of association. All analyses were performed with the statistical package SAS v.9.4 (SAS Institute, Cary, Northern Canada, USA) and two-tailed p-values < 0.05 were considered to be statistically significant.

Ethical aspects. The Ethical Committee of the Northern Ostrobothnia Hospital District approved the study (994/2011), which was performed according to the principles of the Helsinki Declaration of 1983.

The participants took part on a voluntary basis and signed their informed consent. The data were handled on a group level only, personal information being replaced by identification codes resulting in complete anonymity.

Data availability. All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References
1. Beagley, J., Guariguata, L., Weil, C. & Motala, A. A. Global estimates of undiagnosed diabetes in adults. Diabetes Res. Clin. Pract. 103, 150–160 (2014).
2. Tan, T. et al. Inpatient management of diabetic foot problems: summary of NICE guidance. BMJ 342, d1280 (2011).
3. Evans, S. L., Nixon, B. P., Lee, I., Yee, D. & Mooradian, A. D. The prevalence and nature of diabetic problems in elderly diabetic patients. J. Am. Geriatr. Soc. 39, 241–245 (1991).
4. Al-Rubeaan, K. et al. Diabetic foot complications and their risk factors from a large retrospective cohort study. PLoS one 10, e0124446 (2015).
5. Boulton, A. J. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab. Rev. 24, S3–S6 (2008).
6. Singh, N., Armstrong, D. G. & Lipsky, B. A. Preventing foot ulcers in patients with diabetes. JAMA 293, 217–228 (2005).
7. Lavery, L. A., Armstrong, D. G., Wunderlich, R. P., Tredwell, J. & Boulton, A. J. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 26, 1435–1438 (2003).
8. Nather, A. et al. Epidemiology of diabetic foot problems and predictive factors for limb loss. J. Diabetes Complications 22, 77–82 (2008).
9. Bjorsdottir, S. et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin. Infect. Dis. 41, 1416–1422 (2005).
10. Lindström, J. & Tuomilehto, J. The Diabetes Risk Score. A practical tool to predict type 2 diabetes risk. Diabetes Care 26, 725–731 (2003).
11. Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37, 1053–1059 (2001).
12. Mokdad, A. H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76–79 (2003).
13. UKPDS Group, U. K. Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 13, 1–11 (1990).
14. Harris, M. I. & Eastman, R. C. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes. Metab. Res. 16, 230–236 (2000).
15. Ballard, D. J. et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37, 405–412 (1988).
16. Hu, F. B. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25, 1129–1134 (2002).
17. Buijsse, B., Simmons, R. K., Griffin, S. J. & Schulze, M. B. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiologic Reviews 33, 46–62 (2011).
18. Spravchikov, N. et al. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 50, 1627–1635 (2001).
19. Wertheimer, E. et al. Differential roles of insulin receptor and insulin-like growth factor-1 receptor in differentiation of murine skin keratinocytes. J. Invest. Dermatol. 115, 24–29 (2000).
20. Behm, B., Schreml, S., Landthaler, M. & Babilas, P. Skin signs in diabetes mellitus. Journal of the European Academy of Dermatology and Venereology 26, 1203–1211 (2012).
21. Sakai, S., Kikuchi, K., Satoh, J., Tagami, H. & Inoue, S. Functional properties of the stratum corneum in patients with diabetes mellitus: similarities to senile xerosis. Br. J. Dermatol. 153, 319–323 (2005).
22. Yoshipovitch, G. et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 21, 506–509 (1998).
23. Legge, B. S., Grady, J. F. & Lacey, A. M. The incidence of tinea pedis in diabetic versus nondiabetic patients with interdigital macerations: a prospective study. J. Am. Podiatr. Med. Assoc. 98, 353–356 (2008).
24. Perez, M. I. & Kohn, S. R. Cutaneous manifestations of diabetes mellitus. J. Am. Acad. Dermatol. 30, 519–531 (1994).
25. Foss, N., Polon, D., Takada, M., Foss-Freitas, M. & Foss, M. Skin lesions in diabetic patients. Revista de Saúde Pública 39, 677–682 (2005).
26. Galdeano, F., Zaccaria, S., Parra, V., Giannini, M. E. & Salomón, S. Cutaneous manifestations of diabetes mellitus: clinical meaning. Dermatologia Argentina 16, 117–121 (2013).
27. Jelinek, J. Cutaneous manifestations of diabetes mellitus. Int. J. Dermatol. 33, 605–617 (1994).
28. Moriarty, R., Hay, R. & Morris-Jones, R. The diagnosis and management of tinea. BMJ 345, 37–42 (2012).
29. Semel, J. D. & Goldin, H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin. Infect. Dis. 23, 1162–1164 (1996).
30. Dupuy, A. et al. Risk factors for erysipelas of the leg (cellulitis: case-control study. BMJ 318, 1591–1594 (1999).
31. Vanhoote, G., Szepetiuk, G., Paurobally, D. & Heureux, F. Chronic interdigital dermatophytic infection: a common lesion associated with potentially severe consequences. Diabetes Res. Clin. Pract. 91, 23–25 (2011).
32. Cheer, K., Shearman, C. & Jude, E. B. Managing complications of the diabetic foot. Am. Fam. Physician 74, 1163–1168 (2006).
33. Sinikumpu, S. High Prevalence of Skin Diseases and Need for Treatment in a Middle-Aged Population. A Northern Finland Birth Cohort 1966 Study. PhD one 9, e95533 (2014).
34. Burzykowski, T. et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses 46, 496–505 (2003).
35. Ford, E. S., Williamson, D. F. & Liu, S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am. J. Epidemiol. 146, 214–222 (1997).
36. Elässon, N. Cigarette smoking and diabetes. Prog. Cardiovasc. Dis. 45, 405–413 (2003).
37. Gupta, A. K. et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. Journal of the European Academy of Dermatology and Venereology 14, 466–469 (2000).
38. Lindstrom, J. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26, 3230–3236 (2003).
39. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).
40. Everson, S. A., Maty, S. C., Lynch, J. W. & Kaplan, G. A. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J. Psychosom. Res. 53, 891–895 (2002).
41. Winkleby, M. A., Jatulis, D. E., Frank, E. & Fortmann, S. P. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am. J. Public Health 82, 816–820 (1992).
42. Rantakallio, P. Groups at risk in low birth weight infants and perinatal mortality. Acta Paediatrica Scandinavica 193, 1–71 (1969).

Acknowledgements
The study was supported by the Oulu University Hospital, the Northern Finland Cancer Association, the Academy of Finland, the Finnish Medical Foundation, the Medical Research Center Oulu, the Finnish Dermatological Society, the University of Oulu and ERDF European Regional Development Fund - Well-being and health: Research in the Northern Finland Birth Cohort 1966 (grant no. 539/2010 A331592, 01.01.2011–31.12.2013). The study sponsors had no role in this study.

Author Contributions
Conceived and designed the experiments: S.P.S., L.H., K.T., J.A. and S.K.K. Performed the experiments: S.P.S. and L.H. Wrote the first draft of the manuscript: S.P.S. Contributed to the writing of the manuscript: J.A., L.H., K.P., A.R., S.K.K., K.T. and M.T. S.P.S. and K.T. are the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors have read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09354-3

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017